9 النتائج
FIELD OF THE INVENTION
The present invention relates to the diagnosis of breast cancer. It discloses the use of cellular retinoic acid binding protein II in the diagnosis of breast cancer. Furthermore, it especially relates to a method for diagnosis of breast cancer from a liquid sample, derived
FIELD OF THE INVENTION
This invention is in the field of prevention and treatment of cancer. More specifically, this invention relates to the use of 9-cis-retinoic acids and derivatives thereof for treating cancers, in particular breast cancer. This invention also relates to the use of combinations
BACKGROUND OF THE INVENTION
Cancer
Despite many years of research, there exists a compelling need to develop new and more effective therapeutic strategies for cancer. The use of many agents used in cancer treatment is limited because of their cytotoxic effects on normal tissues and cells. This is a
BACKGROUND OF THE INVENTION
Breast cancer kills thousands of women annually. While surgical intervention has saved the lives of many women, radical and partial mastectomies often prove physically and emotionally debilitating. Indeed, surgery, even when combined with chemotherapy, may still expose
BACKGROUND OF THE INVENTION
Breast cancer kills thousands of women annually. While surgical intervention has saved the lives of many women, radical and partial mastectomies often prove physically and emotionally debilitating. Indeed, surgery, even when combined with chemotherapy, may still expose
BACKGROUND OF THE INVENTION
Breast cancer kills thousands of women annually. While surgical intervention has saved the lives of many women, radical and partial mastectomies often prove physically and emotionally debilitating. Indeed, surgery, even when combined with chemotherapy, may still expose
BACKGROUND OF THE INVENTION
Breast cancer kills thousands of women annually. While surgical intervention has saved the lives of many women, radical and partial mastectomies often prove physically and emotionally debilitating. Indeed, surgery, even when combined with chemotherapy, may still expose
BACKGROUND
Field of the Disclosure
The present disclosure relates in general to compositions and methods for inhibiting Pin1 and, more specifically, to all-trans-retinoic acid (ATRA) for modulating Pin1 activity and stability.
Background Information
Cancers represent a leading health problem. The
BACKGROUND
Numerous high-grade malignancies and precancerous conditions exist that are difficult to treat, prevent and eradicate. Many of such conditions are affiliated with breast cancer, prostate cancer, skin cancer, oral cancer, and precancerous conditions thereof. Furthermore, current treatment